Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DEX IR tablets
- Development stage
- Unknown
- Lead developer
- Frank Behrens
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DEX IR tablets is an investigational immediate-release oral tablet formulation of dexamfetamine sulfate (dextroamphetamine sulfate), a central nervous system (CNS) stimulant and small molecule drug. It is being evaluated in the Phase 2 DEXAD clinical trial (NCT06967857) as an adjunctive treatment to SSRIs/SNRIs in adults with attention-deficit/hyperactivity disorder (ADHD) and comorbid moderate to severe major depressive disorder (MDD). Dexamfetamine acts primarily as an agonist of trace amine-associated receptor 1 (TAAR1) and an inhibitor/releasing agent of monoamine transporters, including the dopamine transporter (DAT) and norepinephrine transporter (NET). This mechanism promotes the release and inhibits the reuptake of dopamine and norepinephrine in the synaptic cleft, particularly enhancing activity in the prefrontal cortex to improve sustained focused attention, working memory, and cognitive processes.
- Other names
- DEX IRdexamfetamine sulfate immediate-release tabletsdextroamphetamine sulfate immediate-release tabletsimmediate-release dexamfetamine sulfate tablets
02
Targets
DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)VMAT2 (Vesicular monoamine transporter 2)TAAR1 (Trace amine-associated receptor 1)
Beyond the preview
Go deeper on DEX IR tablets.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DEX IR tablets.